PROMISE Standardized Reporting of PSMA-PET in Prostate Cancer

PROMISE Framework for Standardized PET Imaging of Prostate Cancer

The Prostate Cancer Molecular Imaging Standardized Evaluation
(PROMISE) criteria were established in 2018 and revised in 2023. PROMISE serve as guide for the interpretation of PSMA-PET scans. These scans are advanced diagnostic tools that identify prostate cancer and its dissemination throughout the body.

Why is PROMISE needed?

Data obtained from a PSMA-PET scan can be pivotal in guiding personalized treatment decisions for prostate cancer, such as:

Identifying whether the cancer has metastasized to other body regions.
Detecting the recurrence of prostate cancer following surgery or radiation therapy.
Assessing suitability for PSMA-targeted prostate cancer treatments.

The PROMISE system organizes information from PSMA-PET scans to facilitate accurate and clear communication between physicians and imaging centers. In addition, PSMA-PET findings, when summarized by PROMISE, reveal important information on patient prognosis.

How PROMISE works

PROMISE classifies the extent of disease on a PSMA-PET scan by categorizing it into specific regions: local (T), lymph node (N), and organ (M) spread. Disease extent and location is reported for all body regions and summarized in a comprehensive diagnosis code.

Standardized reading of PSMA-PET can be performed using the ePROMISE Online Application.

Standardized reading of PSMA-PET can also be performed on paper using the PROMISE Pocket Card

PROMISE PET Registry

PSMA-PET imaging and the PROMISE framework are linked to prostate cancer outcomes. To deepen our understanding of the relationship between PET imaging and patient survival rates, we have established an international registry study for PET imaging centers.